‘Game-changing’ Alzheimer’s drug lecanemab gets green light in the UK but WON’T be available on the NHS
A “GAME-CHANGING” drug shown to slow the progression of Alzheimer’s has been approved in the UK.
Lecanemab, developed by pharmaceutical company Eisai, is a targeted antibody treatment that binds to amyloid – a protein which builds up in the brains of people living with the disease.
GettyA drug to slow down Alzheimer’s has been approved in the UK[/caption]It is designed to help clear the build-up and slow down cognitive decline, and is given to patients via an intravenous drip fortnightly.
Заголовки